Answers are grounded in this paper and cite their sources.
Demonstrates dual antibacterial and osteogenic effects in a hydrogel for peri-implantitis, suggesting a minimally invasive treatment option.
Peri-implantitis is a biofilm-associated infectious disorder marked by progressive peri-implant bone loss and remains a major cause of late implant failure. To achieve simultaneous antibacterial treatment and bone regeneration, an injectable charge-complementary hydrogel (BMP-2@HA/ε-PL) was fabricated using anionic hyaluronic acid (HA), cationic ε-poly-L-lysine (ε-PL), and positively charged bone morphogenetic protein-2 (BMP-2). Its structural and physicochemical features were examined by Fourier-transform infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), rheological testing, compression analysis, and swelling-degradation behavior assessments. BMP-2 release was quantified by enzyme-linked immunosorbent assay (ELISA). In vitro, cytocompatibility of the BMP-2@HA/ε-PL hydrogel with rat bone marrow mesenchymal stem cells (BMSCs) was evaluated by CCK-8 and Live/Dead staining, whereas osteogenic differentiation was assessed by alkaline phosphatase (ALP) activity, calcium deposition, and expression of osteogenesis-related genes. Antibacterial activity in vitro was evaluated against Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli). The results demonstrated the successful synthesis of the hydrogels, and BMP‑2 incorporation optimized the physicochemical properties (a densely packed network, higher compressive strength, and slower degradation) of the BMP‑2@HA/ε‑PL hydrogel, which also showed effective BMP‑2 release. In vitro evaluation further indicated that the BMP‑2@HA/ε‑PL hydrogel exhibited favorable cytocompatibility, enhanced osteogenic differentiation of BMSCs due to the synergistic effect of HA and BMP‑2, and robust antibacterial effects against both S. aureus and E. coli. These findings indicate that the injectable BMP‑2@HA/ε‑PL hydrogel features dual antibacterial and osteoinductive functions, offering a promising minimally invasive strategy for peri-implantitis treatment.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: